JAAD/JID Junction

The Journal of the American Academy of Dermatology (JAAD) and the Journal of Investigative Dermatology (JID) are pleased to announce an article exchange program. This opportunity is made possible through a reciprocal partnership between the journals.

The featured articles appearing in JAAD and JID are freely available to the journals’ readers.


May


BRAF Inhibitors in Melanoma Management: When Friends Become Foes

Vemurafenib improves survival of patients with melanoma with BRAFV600E mutations. However, in melanomas with dual mutations in BRAF and NRAS vemurafenib selectively enhances expression of genes involved in the epithelial-to-mesenchymal transition in BRAFV600E/NRASQ61K melanoma cells, paradoxically promoting tumor growth and metastasis in mice. This preclinical study provides compelling reasons to be cautious in the use of BRAFis in patients with NRAS-driven melanoma.

Risk of psoriasis according to body mass index: A retrospective cohort analysis

Narrative: It is now well established that obesity and metabolic syndrome are comorbidities that are more frequent in patients with psoriasis. Using a retrospective cohort analysis involving more than 1.5 million individuals in the United States, Norden and colleagues determine that incidence of psoriasis is increased in those who are overweight and, among the obese, that incidence is proportional to obesity class.


April


Temporal Outcomes after Rituximab Therapy for Pemphigus Vulgaris

IgG lasts about 6 months in circulation and pemphigus antibodies continue to circulate after rituximab therapy. In this study, a >90.7% reduction in average desmoglein 3 ELISA titers from baseline to months 3-9 was 94% sensitive, and an average absolute titer 130 RU/ml between months 3 and 9 was 96% specific, for achievement of complete remission off oral systemic therapy.

Real-world comorbidities of atopic dermatitis in the US adult ambulatory population

It is now accepted that psoriasis has systemic dimensions with multiple associated comorbidities. In a large study of health care-related commercial claims and encounters, Roh and colleagues use multivariable logistic regressions and report that adult ambulatory patients with atopic dermatitis demonstrate increased odds of several psychiatric diseases, autoimmune disorders and infections, as well as lymphoid/hematologic malignancy, atherosclerosis and metabolic syndrome. Multispecialty management of these patients may be indicated.


March


Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis

Checkpoint inhibitors have revolutionized medical oncology and they are now in common use. In this retrospective study involving a national claims database, Wongvibulsin and coworkers document strikingly frequent (25%) cutaneous immune-related adverse events of various types within a few months of treatment initiation.

Merkel Cell Polyomavirus-Negative Merkel Cell Carcinoma Originating from In Situ Squamous Cell Carcinoma: A Keratinocytic Tumor with Neuroendocrine Differentiation

Polyoma virus-negative Merkel cell carcinoma is an aggressive tumor frequently seen in older sun-damaged individuals. In this study,whole-exome sequencing of four combined tumors consisting of SCC in situ and Merkel cell polyomavirus-negative MCC showed many mutations shared between SCC and MCC in all cases, implying a keratinocytic origin of these MCCs.


February


A cross-sectional study of ethnoracial representation in pediatric plaque psoriasis clinical trials

In the February issue of the JAAD, Mosca describe ethnoracial representation in selected pediatric clinical trials involving patients with psoriasis. Children and adolescents with skin of color were underrepresented, especially when disease prevalence was considered. Proactive efforts to address this and related issues are required.

The IL-1 Pathway Is Hyperactive in Hidradenitis Suppurativa and Contributes to Skin Infiltration and Destruction

The IL-1β pathway represents a pathogenetic cascade, whose activity may be targeted therapeutically.


January


The Sensation of Itch: From Biological Discovery to Medical Treatment

This is a great introduction to recent advances in our understanding of itch and new therapeutic targets.

Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry

Responses to biologics in patients with psoriasis are not universal and it would be useful to have predictors of good responders and lesser responders. Enos and colleagues leveraged the CorEvitas' Psoriasis Registry and determined that obesity and diabetes were associated with reduced responsiveness to biologics. Subgroup analysis suggested that selected comorbidities were differentially associated with responsiveness to individual agents.


December


Genotype‒Structurotype‒Phenotype Correlations in Patients with Pachyonychia Congenita

Pachyonychia congenita-associated oral leukokeratosis correlates with K6A mutations whereas cutaneous cysts, follicular hyperkeratosis, and natal teeth correlate with K17 mutations. Painful keratoderma is prominent with K6A and K16 mutations. Nail involvement was most common in patients with K6A mutation and least common in those with K6C mutation.

Association of herpes zoster and chronic inflammatory skin disease in US inpatients

Herpes zoster (HZ) is common and debilitating, and an efficacious vaccine exists. When Chovatiya and Silverberg surveyed a large Nationwide Inpatient sample over a 10 year period, they determined that many chronic inflammatory skin diseases (CSIDs) were associated with increased hospitalization for HZ, and some of the adjusted odds ratios were quite large. HZ vaccine guidelines for patients with CISDs may require modification.


November


Inhibition of PAI-1 Blocks PD-L1 Endocytosis and Improves the Response of Melanoma Cells to Immune Checkpoint Blockade

While anti–PD-1/PD-L1 monotherapy has revolutionized melanoma treatment, only a subset of patients exhibits long-term tumor remission, and the underlying mechanism of resistance to PD-1/PD-L1 inhibitors remains unclear. This study suggests that cell surface retention of PD-L1 is inversely correlates with PAI-1 expression in vitro, in vivo, and in clinical specimens. Moreover, extracellular PAI-1 induced the internalization of surface-expressed PD-L1 by triggering clathrin-mediated endocytosis. Targeting PAI-1 by tiplaxtinin synergizes with anti–PD-L1 immune checkpoint blockade therapy in a syngeneic murine model of melanoma, suggesting this may be a promising therapeutic regimen for melanoma treatment.

Complete and transparent reporting of primary end points of randomized trials in the dermatology literature: A comparison of registered and published primary end points

Still room for improvement
Dermatology has a rich tradition of anecdotal literature that has recently been complimented by rigorous clinical research. In this issue of the JAAD, Kim and colleagues report that there is still room for improvement even among randomized clinical trials.


October


Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies

Narrative: JAK inhibitors are potent anti-inflammatory agents but toxicities may limit systemic administration. In an encouraging report, Papp and coworkers indicate that topical ruxolitinib is active and well tolerated in phase 3 randomized, double-blind studies of adults with atopic dermatitis.

Impact of Biological Agents on Imaging and Biomarkers of Cardiovascular Disease in Patients with Psoriasis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials

Randomized controlled trials suggest that ustekinumab reduces aortic vascular inflammation and that both TNF-alpha inhibitors and phototherapy can reduce CRP and IL-6. These are surrogate markers for risk of cardiovascular disease and randomized controlled trials evaluating cardiovascular events are needed to confirm these findings.


September


Prurigo Nodularis Is Characterized by Systemic and Cutaneous T Helper 22 Immune Polarization

Both systemic and cutaneous immune responses in PN are skewed toward a Th22/IL-22 profile suggesting that patients may benefit from immunomodulatory therapies directed at Th22-mediated inflammation.

Psoriasis is not associated with cognition, brain imaging markers, and risk for dementia: The Rotterdam Study

Psoriasis is recognized to be a systemic illness with a number of significant comorbidities. In a population based study, Pezzolo and colleagues did not detect an association between the diagnosis of psoriasis preclinical markers or higher risk of dementia.


August


Myeloid Dendritic Cells Are Major Producers of IFN-β in Dermatomyositis and May Contribute to Hydroxychloroquine Refractoriness

Dermatomyositis pathogenesis has been linked to IFN-1 response and myeloid dendritic cells producing IFN-b are significantly increased in the skin of hydroxychloroquine nonresponders compared with responders suggesting they contribute to hydroxychloroquine refractoriness.

A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results

JAK inhibitors block multiple cytokine signaling pathways and they are promising therapeutics for inflammatory skin diseases. In a randomized placebo-controlled phase 2a trial, King and coworkers demonstrate that systemic administration of ritlecitinib and brepocitinib to alopecia areata patients with >50% scalp hair loss results in objective responses and is well-tolerated at 24 weeks.


July


Efficacy and Safety of Tacrolimus 0.1% for the Treatment of Facial Vitiligo: A Multicenter Randomized, Double-Blinded, Vehicle-Controlled Study

In this study, twice-daily tacrolimus 0.1% ointment was superior to vehicle through the 24 weeks of intervention and 24 weeks of follow-up in adult patients with facial vitiligo. In the age of JAK inhibitors, we should remember other agents that may also benefit vitiligo patients.

Metformin is associated with decreased risk of basal cell carcinoma: A whole-population case-control study from Iceland

Metformin is an inexpensive and well tolerated oral hypoglycemic agent that is being touted as a treatment or preventative for a variety of diseases. Based on a retrospective study from Iceland, Adalsteinsson et al. report that metformin intake was associated with decreased risk of basal cell carcinoma. Confirmation of efficacy and determination of mechanism of action could result in development of practical chemoprevention for this most common cancer.


June


Cigarette Smoke Underlies the Pathogenesis of Palmoplantar Pustulosis via an IL-17A–Induced Production of IL-36γ in Tonsillar Epithelial Cells

Dermatologists are aware of the strong association between smoking and palmoplantar pustulosis. IL-36 plays a pivotal role in the pathogenesis of pustular psoriasis and this in vitro study revealed that IL-17A induces a release of IL-36γ under cigarette smoke extract exposure.

Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: A population-based study

Methotrexate has been a mainstay of psoriasis therapy for decades. Monitoring for hepatoxicity in these patients has been influenced by the experience of rheumatologists using methotrexate for rheumatoid arthritis. This study suggests that a more conservative approach may be necessary for methotrexate-treated patients with psoriasis and/or psoriatic arthritis.


May


Evaluation of platelet-rich plasma on hair regrowth and lesional T-cell cytokine expression in alopecia areata: A randomized observer-blinded, placebo-controlled, split-head pilot study

In dermatology, rigorous testing of interventions in diseases that exhibit periodicity does not always occur. In addition, the results of "negative studies" may not be published as frequently as others. In this issue of the JAAD, Gupta and colleagues describe a small observer-blinded, placebo-controlled study of PRP in AA. The results do not provide support for enthusiastic use of this intervention in this disease. The authors and the JAAD are to be commended.

Epigenetic alterations in keratinocyte carcinoma

Drug discovery relies on evolving knowledge of disease pathogenesis. In the case of skin carcinogenesis there has been much research into genetic mutations. This study delves into epigenetic alterations that drive carcinogenesis and may pave the way to drug discovery including enriched epidermal development and Wnt signaling pathways in basal cell carcinoma and enriched immune response and cell activation pathways in SCCs. The authors also observed enrichment of transcription factors implicating SMAD and JDP2 in BCC pathogenesis and FOXP1 in SCC pathogenesis.


April


Incidence of psoriasis among adults in the United States: A sex- and age-adjusted population analysis

The existence and availability of electronic medical records can facilitate timely large clinical research studies that would otherwise not be possible. In this paper in the JAAD, Burshtein and colleagues provide updated contemporary information about psoriasis in the USA.

A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans

Similar to imatinib, pazopanib may be useful in the setting of unresectable dermatofibrosarcoma protuberans (DFSP). In this study, 9 patients (39%) discontinued the treatment because of adverse events.


March


A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: Secondary efficacy and patient-reported outcomes

Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis

Two papers in the March 2021 issue of the JAAD indicate that tapinarof cream, a novel topical aryl hydrocarbon receptor (AHR) modulating agent, is tolerated and has activity in both psoriasis and atopic dermatitis. Future mechanistic studies involving this nonsteroidal anti-inflammatory agent will be of great interest.

Cancer-Associated Fibroblasts Play an Important Role in Early-Stage Mycosis Fungoides

Most therapeutic interventions for cutaneous T-cell lymphoma focus on the malignant lymphocytes, but emerging data suggest that fibroblasts promote the malignancy by increasing the motility and chemo-resistance of malignant T cells. Targeting these fibroblasts may be of therapeutic value.


February


Clinical benefit of baseline imaging in Merkel cell carcinoma: Analysis of 584 patients

Advances in immunotherapy for Merkel Cell Carcinoma (MCC) therapy coupled with dramatic improvements in outcome have prompted re-evaluation of diagnostic workups. In this issue, Singh and colleagues describe a retrospective study of 584 patients with a cutaneous primary MCC and no evidence of distant metastases. Baseline imaging determined that 13.2% of patients with clinically node-negative disease had occult metastatic disease that warranted systemic intervention.

Which Way Do We Go? Complex Interactions in Atopic Dermatitis Pathogenesis

From barrier dysfunction to inflammation — insights on the treatment of atopic dermatitis.


January


JAAD 84: 46, 2021
The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: A systematic analysis from the Global Burden of Disease Study 2017

Those of us in the developed western world are well aware that psoriasis is prevalent and that it is has a large aggregate impact on regional human health. We are less aware of the extent to which psoriasis is problematic worldwide. In this issue of the JAAD, Mehrmal and colleagues report on the significant global, regional and national burden of psoriasis as determined from the Global Burden of Disease Study 2017.

Treatment of Advanced Melanoma in 2020 and Beyond

An excellent review of the rapidly evolving field of melanoma therapy.


December


JAAD 83: 1770, 2020
https://www.jaad.org/article/S0190-9622(20)30490-4/fulltext

Under-represented minority (URM) individuals are especially under-represented in dermatology and perhaps even more so in academic dermatology. Pipeline issues are often identified as barriers to timely implementation of remedies. In this issue of the JAAD, investigators from the University of Texas describe some barriers reported by applicants to the UTSW Dermatology Residency Program.

Propranolol Is an Effective Topical and Systemic Treatment Option for Experimental Epidermolysis Bullosa Acquisita

A potential game changer: Based on its molecular impact on immune complex–activated neutrophils, propranolol has potential as a treatment for neutrophil-mediated inflammatory skin diseases.


November


JAAD 83:1282, 2020
https://www.jaad.org/article/S0190-9622(20)31152-X/fulltext

Although it is well recognized that children are not little adults, children are typically excluded from early clinical trials of novel systemic therapeutics. In the issue of the JAAD, Paller and many coworkers report the results of a phase 3 double-blind trial of dupilumab in children age 6-11 years old with severe AD. In this short trial, dupilumab was safe and effective in children as previously reported in adults.

Drug Resistant Melanoma May Be Vulnerable to Inhibitors of Serine Synthesis

Roughly 45% of all melanoma cases are driven by an activating BRAF mutation targetable by BRAF inhibitors in combination with MAPK/extracellular signal–regulated kinase kinase (MEK) inhibitors or αPD- 1 antibodies. Activating mutations in NRAS are responsible for roughly 20% of melanomas, and these tumors rapidly develop resistance to MEK inhibitors. Increased expression of phosphoglycerate dehydrogenase (PHGDH) is required for NRAS melanoma resistance to targeted MEK inhibition, suggesting possible therapeutic targets.


October


JAAD 83:1212, 2020 and 83:1215, 2020
https://www.jaad.org/article/S0190-9622(20)32185-X/fulltext
https://www.jaad.org/article/S0190-9622(20)32099-5/fulltext

Determining best practices for initiation and/or continuation of systemic immunomodulatory therapies during the COVID-19 pandemic has been challenging. These brief Letters in the October 2020 issue of the JAAD exemplify efforts of thoughtful expert clinicians and clinical researchers who provide desperately needed guidance based on necessarily incomplete knowledge.

Research Techniques Made Simple: Developing and Validating QOL Outcome Measures for Skin Diseases

This article provides a framework for development of sound dermatologic QOL assessment tools through the presentation of two established and validated tools, the Skindex and ItchyQoL.


September


Standardizing Hidradenitis Suppurativa Skin Microbiome Research: The Methods Matter

Standardized methods will produce more relevant outomes.

Melanoma incidence, stage, and survival after solid organ transplant: A population-based cohort study in Ontario, Canada

Transplant recipients developed more melanoma and more advanced melanomas, and even early melanomas were associated with increased all-cause mortality.


August


A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain

New agents are in the pipeline for treatment of HS.

Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries

A large registry case series suggests an association of distinctive skin lesions with COVID-19 – rapid progress enabled by international collaboration and the internet.


July


Meeting Report of the 16th International Langerhans Cell Workshop: Recent Developments in Langerhans Cell and Skin Dendritic Cell Biology and their Therapeutic Application

Groundbreaking translations research with direct applications to patient care.

Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo

Remarkable improvement in prurigo nodules was noted in a small, multicenter, retrospective trial of dupilumab.


June


The Identification of Potential Therapeutic Targets for Cutaneous Squamous Cell Carcinoma

Groundbreaking translations research with direct applications to patient care.

Where you live matters: Regional differences in health care resource use for psoriasis in the United States

Health care disparities are common and multifactorial.


May


A Spectrum of Skin Disease: How Staphylococcus aureus Colonization, Barrier Dysfunction, and Cytokines Shape the Skin

S. Aureus colonization may play a role in a variety of skin conditions, especially barrier function.

Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data

Disease heterogeneity of HS complicates interventional studies in patients with HS. Deliberate selection and specification of outcome measures and study endpoints during pretrial planning is essential.


April


Mechanisms of Itch in Stasis Dermatitis: Significant Role of IL-31 from Macrophages

Relevant targets for biologic therapy.

Greater efficacy of SPF 100+ sunscreen compared with SPF 50+ in sunburn prevention during 5 consecutive days of sunlight exposure: A randomized, double-blind clinical trial

Incremental clinical benefits of very high (100+) SPF sunscreens have been debated. An actual use at the beach study confirms that 100+ SPF sunscreens are more efficacious than 50+ SPF sunscreens.


March


A Genetic Variant in the BCL2 Gene Associates with Adalimumab Response in Hidradenitis Suppurativa Clinical Trials and Regulates Expression of BCL2

Possible predictor of biologic response to therapy.

Tonsillitis and pediatric psoriasis: Cohort and cross-sectional analyses of offspring from the Danish National Birth Cohort

A relationship between streptococcal infections and guttate psoriasis is accepted. This Danish study suggests that in selected age groups, recurrent tonsillitis may be associated with pediatric psoriasis.


February


Survival in Mycosis Fungoides and Sezary Syndrome: How Can We Predict Outcome?

Evolving data on predicting outcomes with cutaneous T cell lymphoma variants.

Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events

A single center prospective study of patients with advanced melanoma who were treated with PD-1 inhibitors suggests that development of one or more occurrences of common cutaneous events was associated with improved outcomes.


January


IL-17A Softens the Skin: Antifibrotic Properties of IL-17A in Systemic Sclerosis

Potential for biologic targets in the treatment of system sclerosis.

Exploring changes in placebo treatment arms in hidradenitis suppurativa randomized clinical trials: A systematic review

The magnitudes of placebo responses in studies of patients with HS and the impact of placebo on assessments of physical signs and pain in HS may be surprising. Implications for clinical research and clinical care are discussed.


December


Second-Hit Somatic Mutations in Mevalonate Pathway Genes Underlie Porokeratosis

Porokeratosis is associated with mutations in mevalonate pathway genes and can respond to topical therapy.

Dirk M. Elston, M.D.
Editor
Journal of the American Academy of Dermatology

Mark C. Udey, M.D., Ph.D.
Editor
Journal of Investigative Dermatology


November


Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade

Bispecific antibodies have the potential to provide a more specific targeted immune response against tumors.

Dirk M. Elston, M.D.
Editor
Journal of the American Academy of Dermatology

Mark C. Udey, M.D., Ph.D.
Editor
Journal of Investigative Dermatology


October


ILC2s and Basophils Team Up to Orchestrate IL-33—Induced Atopic Dermatitis

Better understanding of mechanisms of atopic dermatitis opens the door for more effective targeted therapy.

Dirk M. Elston, M.D.
Editor
Journal of the American Academy of Dermatology

Mark C. Udey, M.D., Ph.D.
Editor
Journal of Investigative Dermatology


September


Can Combination MEK and Akt Inhibition Slay the Giant Congenital Nevus?

We may be entering an age where medical management of giant congenital nevi becomes a possibility.

Dirk M. Elston, M.D.
Editor
Journal of the American Academy of Dermatology

Mark C. Udey, M.D., Ph.D.
Editor
Journal of Investigative Dermatology


August


Temporal Changes in Size and Dermoscopic Patterns of New and Existing Nevi in Adolescents

Most nevi retain a stable dermoscopic pattern. For those that do change, the most common shift was towards a reticular pattern. Nevi with predominant reticular and globular patterns infrequently changed from one pattern to the other with the exception of those with a peripheral rim of globules. As they stop enlarging, they lose their peripheral globules. Read the JID article from Haoming Xu and colleagues .

A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation

Bullous diseases without blisters? In this issue of the JAAD, the late Marcel Jonkman and his colleagues at the University of Groningen in the Netherlands describe their experience with a cohort of patients who carry the diagnosis of nonbullous pemphigoid based on a retrospective single institution study.

Dirk M. Elston, M.D.
Editor
Journal of the American Academy of Dermatology

Mark C. Udey, M.D., Ph.D.
Editor
Journal of Investigative Dermatology


July


Mechanical Stretch Exacerbates Psoriasis by Stimulating Keratinocyte Proliferation and Cytokine Production

Qiao and colleagues shed some additional light on the phenomenon of koebnerization in the July issue of JID.

A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation

Systemic immunosuppressive medications are increasingly used in patients with chronic inflammatory skin diseases, including psoriasis. Administration of recombinant herpes zoster vaccine in these patients seems prudent, especially in patients > 50 years old. Read the article by Baumrin and colleagues in the July issue of JAAD.

Dirk M. Elston, M.D.
Editor
Journal of the American Academy of Dermatology

Mark C. Udey, M.D., Ph.D.
Editor
Journal of Investigative Dermatology


June


Gene Therapy for Epidermolysis Bullosa

Advances in our understanding of the molecular biology of the dermal-epidermal basement membrane have led to the first clinical trials of gene therapy for JEB and RDEB and the potential to make positive changes in the lives of patients with EB. Read the article by Marinkovich and Tang in the June issue of JID.

Developing an international standard for the classification of surface anatomic location for use in clinical practice and epidemiologic research

Unambiguous communication of research findings depends on usage of accepted terminology. This article in the June issue of the JAAD codifies a lexicon of descriptors that should be useful in clinical research and perhaps in clinical practice as well.

Dirk M. Elston, M.D.
Editor
Journal of the American Academy of Dermatology

Mark C. Udey, M.D., Ph.D.
Editor
Journal of Investigative Dermatology


May


Cochrane Reviews and Dermatological Trials Outcome Concordance: Why Core Outcome Sets Could Make Trial Results More Usable

In the May issue of JID, Jochen Schmitt and colleagues present evidence that evidence-based recommendations are limited by the lack of standardized outcome measures in clinical trials. They suggest the development of key outcomes measures to be reported in all trials.

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial

Purigo nodularis is an understudied disorder that can be associated with debilitating itch. In the May issue the JAAD, Stander and coworkers describe the results of a multi-center, phase 2, randomized, placebo-controlled trial that was conducted in Germany. They report that the neurokinin 1 receptor antagonist serlopitant was well tolerated and that it significantly reduced pruritis over the 8 week study period.

Dirk M. Elston, M.D.
Editor
Journal of the American Academy of Dermatology

Mark C. Udey, M.D., Ph.D.
Editor
Journal of Investigative Dermatology


April


Risk of Second Primary Cancer in Survivors of In Situ Melanoma

Patient with a history of in situ melanoma have an increased risk of developing lip, thyroid, pancreatic, and brain cancers and decreased risks of head and neck, and lung cancers. In this JID article, Michael Kimlin and colleagues report that male patients had a significantly increased risk of prostate cancer, while females had an increased risk of thyroid cancer and lymphoid leukemia.

Treatment of primary nonmetastatic melanoma at high-volume academic facilities is associated with improved long-term patient survival

In this April issue of JAAD, Shayan Cheraghlou and colleagues report that results from a nationwide study suggest that patients with nonmetastatic primary melanoma benefit from evaluation and treatment at centers characterized by high patient volume and academic affiliation. This observation may prompt discussion of the role of community practitioners in the care of these patients.

Dirk M. Elston, M.D.
Editor
Journal of the American Academy of Dermatology

Mark C. Udey, M.D., Ph.D.
Editor
Journal of Investigative Dermatology


March


Who Needs a Skin Exam? Skin Cancers in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the Contemporary Era

This month's JID includes an excellent review of advances in transplantation and the risk of cutaneous malignancy by de Masson and colleagues. This articles serves as a commentary on an Original Article on the topic by Wu and colleagues.

Comparison of tumor staging systems for cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia

Rigorous clinical research requires accepted diagnostic criteria that infer outcomes and validated disease assessment tools. It is increasingly clear that cancer outcomes are influenced by both patient and tumor characteristics. In the March JAAD, Inda and colleagues report that the Brigham and Women's Hospital staging system outperformed AJCC7 criteria for cutaneous squamous cell carcinoma in patients with CLL.

Dirk M. Elston, M.D.
Editor
Journal of the American Academy of Dermatology

Mark C. Udey, M.D., Ph.D.
Editor
Journal of Investigative Dermatology


February


The Biology and Clinical Features of Cutaneous Polyomaviruses

Human polyomaviruses have been linked to a variety of diseases that range from Merkel cell carcinoma to trichodysplasia spinulosa. This month's JID features a nice review of the genomic and clinical features of cutaneous polyomaviruses by Nguyen and colleagues.

Additional Utility for Checkpoint Inhibitors (?)

Advanced basal cell carcinomas (BCCs) are rare and highly problematic. Immune checkpoint inhibitors including anti-PD-L1 antibodies are highly effective in subsets of patients with advanced melanoma and other cancers that feature high mutation loads. Results of a small pilot study conducted by Chang and coworkers suggest that pembrolizumab has activity in patients with advanced BCCs.

Dirk M. Elston, M.D.
Editor
Journal of the American Academy of Dermatology

Mark C. Udey, M.D., Ph.D.
Editor
Journal of Investigative Dermatology


January


Are bacteria infectious pathogens in hidradenitis suppurativa (HS)? Debate at the Symposium for Hidradenitis Suppurativa Advances meeting (November 2017)

There have been substantial advances in the treatment of hidradenitis suppurative, but the role of infectious organisms remains only partially defined. The proceedings covered in this JID Meeting Report by Naik and colleagues address the emerging evidence surrounding the role of infectious organisms and the impact on treatment.

Dupilumab does not affect correlates of vaccine-induced immunity: a randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis

The availability of targeted biologics allows careful assessment of the involvement of selected cytokines in human immune responses. In this month’s JAAD, Blauvelt and colleagues report that administration of anti-IL-4 receptor alpha antibodies to AD patients does not prevent humoral responses to tetanus or meningococcal polysaccharide vaccines.

Dirk M. Elston, M.D.
Editor
Journal of the American Academy of Dermatology

Mark C. Udey, M.D., Ph.D.
Editor
Journal of Investigative Dermatology


December


Progress in Understanding Atopic Dermatitis

We are entering a new era of treatment options for atopic dermatitis. This commentary by Jon M. Hanifin in JID gives an overview of advances in our understanding of the disease.

Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study

Checkpoint inhibitors have revolutionized medical oncology, but responses vary. In a single-center, retrospective, case-control study, Lee and coworkers report in the JAAD that de novo occurrence of "dermatitis" was associated with improved outcomes. Larger prospective studies are indicated.

Dirk M. Elston, M.D.
Editor
Journal of the American Academy of Dermatology

Mark C. Udey, M.D., Ph.D.
Editor
Journal of Investigative Dermatology


November


The Anti-Inflammatory Activities of Propionibacterium acnes CAMP Factor-Targeted Acne Vaccines

While much work remains to be done, this JID article by Yanhan Wang and colleagues provides intriguing proof of concept that inflammatory mediators of acne could be targeted by vaccines.

Fibroproliferative genes are preferentially expressed in central centrifugal cicatricial alopecia

Pathogenic mechanisms responsible for scarring alopecias are incompletely understood and current therapies are inadequate. Aguh and colleagues utilize contemporary gene expression techniques and centrifugal cicatricial alopecia patient-derived samples in hypothesis generating studies that are reported in the JAAD.

Dirk M. Elston, M.D.
Editor
Journal of the American Academy of Dermatology

Mark C. Udey, M.D., Ph.D.
Editor
Journal of Investigative Dermatology


October


Topical Antiseptics and the Skin Microbiota

Most of the human biome is anaerobic, but as we don’t isolate these organisms in aerobic culture they have been in our "blind spot" for many years. Studies using sequencing rather than culture have improved our knowledge of the true spectrum of skin flora. In this JID study by Jan Claesen, the effects of topical antiseptics on skin flora were evaluated. Propionibacteriaceae are very resilient compared with other organisms.

Ethnic Differences and Comorbidities of 909 Prurigo Nodularis Patients

Health disparity-related research is underemphasized in our specialty. In this recent JAAD paper, Boozalis and colleagues begin to carefully characterize patients with an uncommon, but not rare, and sometimes disabling condition.

Dirk M. Elston, M.D.
Editor
Journal of the American Academy of Dermatology

Mark C. Udey, M.D., Ph.D.
Editor
Journal of Investigative Dermatology


September


JAK Inhibitors for Treatment of Alopecia Areata

JAK inhibitors have demonstrated tremendous potential in the treatment of difficult conditions, including alopecia areata and vitiligo. This JID article by Eddie H. C. Wang and colleagues summarizes evidence supporting their use in the treatment of alopecia areata.

CARD Carrying Patients

Keith Choate and colleagues studied 15 kindreds including patients with CARD14-associated papulosquamous eruption (CAPE). Affected individuals exhibited clinical features of psoriasis and/or PRP, and some responded to treatment with ustekinumab.

Dirk M. Elston, M.D.
Editor
Journal of the American Academy of Dermatology

Mark C. Udey, M.D., Ph.D.
Editor
Journal of Investigative Dermatology


August


Sample Size Estimation and Power Calculation

Sample size is key to valid research. An article by Schmidt and colleagues in this month’s JID Connector series on Research Techniques Made Simple provides a good overview of the process of estimation of appropriate sample size and power calculation.

Sex and Melanoma

Melanoma prognosis is influenced by immune status and immunity-augmenting therapeutics are efficacious in some patients. Sinnamon et al. report in the JAAD that tumor-infiltrating lymphocyte (TIL) frequency in primary melanomas was more relevant in men than women. Sex differences may prove to be important considerations that relate to therapy choices and disease outcomes.

Dirk M. Elston, M.D.
Editor
Journal of the American Academy of Dermatology

Mark C. Udey, M.D., Ph.D.
Editor
Journal of Investigative Dermatology


July


Dapsone hypersensitivity

Dapsone remains a key drug in the dermatologist’s armamentarium, but serious and life-threating reactions can occur. A study of Taiwanese individuals by Chen and colleagues in this month’s JID confirms that HLA-B*13:01 is strongly associated with dapsone-induced DRESS and sheds light on a functional role for the HLA-restricted immune mechanisms that may be involved.

Cardiovascular disease in treated psoriasis

Psoriasis is a systemic inflammatory disease with increased cardiovascular disease-associated mortality risk. The discovery of potent, well-tolerated anti-inflammatory biologic agents provides opportunities to test the cardiovascular disease modifying activities of new systemic psoriasis treatments. Two industry sponsored studies in this month’s issue of the JAAD focus on cardiovascular disease-related effects of TNF alpha inhibitory and anti-IL-17A monoclonal antibodies. Some of the challenges and limitations of these types of studies are discussed in a Commentary by Joel Gelfand.

Dirk M. Elston, M.D.
Editor
Journal of the American Academy of Dermatology

Mark C. Udey, M.D., Ph.D.
Editor
Journal of Investigative Dermatology

Advertisement